908 Devices EPS
The Earnings per Share (EPS) of 908 Devices (MASS) as of Jul 24, 2026 is -2.12 USD. In the previous year, Earnings per Share (EPS) was -1.13 USD — a change of 87.68% (lower).
Get this data via API
Financial Data API
EPS
-2.12USD
YoY
87.68%
Last updated:
Earnings per Share (EPS) of 908 Devices is 2026 -2.12 USD. Earnings per Share (EPS) of 908 Devices was 2025 -1.13 USD. It decreases by 87.68% lower compared to the previous year.
Access this data via the Eulerpool API
908 Devices Stock analysis
What does 908 Devices do? The company 908 Devices was founded in Boston in 2012 and specializes in the development and manufacturing of innovative analysis devices. The idea behind the company was to develop portable devices that would allow users to perform quick and accurate analyses on-site.
908 Devices' business model is based on the development and marketing of devices for the chemistry, pharmaceutical, and biotech industries, as well as for applications in the security and defense sectors. The company has several product lines tailored to different applications, including portable devices for mobile use.
One of the most important branches of 908 Devices is mass spectrometry, a method used in many areas of analytics, such as forensics, environmental analysis, and food control. 908 Devices has developed a technology that allows for compact and portable mass spectrometry, which was not previously possible.
Another important area of 908 Devices is chromatography, a method used for separating substances. Here too, the company has developed a technology that allows for the offering of chromatography in portable devices.
908 Devices also offers devices for molecular spectroscopy, including Raman spectroscopy, which allows for the identification and characterization of molecules. Raman spectroscopy is used in many applications, such as pharmaceutical research and material analysis.
Among the products offered by 908 Devices are the M908 and MX908 devices, specifically designed for use in the security and defense industry. These devices allow for the real-time detection of a variety of hazardous substances, such as explosives, drugs, or dangerous chemicals.
Another product of 908 Devices is the ZipChip device, used in biotech research. The ZipChip allows for the analysis of proteins in a very short time, which is of great importance in pharmaceutical research.
The company has received several awards in recent years, including the R&D 100 Award and the Innovation Award of Analytica, one of the world's most important trade fairs for analytics and laboratory technology.
Overall, 908 Devices has achieved an impressive success story and aims to revolutionize the way analyses are conducted. With its innovative products and technologies, the company has found a niche in the market and has experienced strong growth. 908 Devices is one of the most popular companies on Eulerpool.
Frequently Asked Questions about 908 Devices stock
Earnings per Share (EPS) of 908 Devices is -2.12 USD in 2026.
Access this data via the Eulerpool API
Income Statement — 908 Devices
All Key Metrics — 908 Devices
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth